The synthetic CB1 cannabinoid receptor selective agonists: Putative medical uses and their legalization

Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance

“…Intriguingly, as shown in Figure 2 , both positive and negative changes in their effects may occur under the same pathological condition (described in detail previously by [ 6 , 9 , 11 , 12 , 13 , 14 ]). Thus, CB 1 R activation may have beneficial effects against loss of appetite and body weight, nausea, spasticity in multiple sclerosis, pain (especially peripherally-restricted CB 1 R agonists), anxiety- and depressive-like behavior, posttraumatic stress disorder, neuroprotection, and epilepsy [ 9 , 15 , 16 , 17 , 18 ] or may lead to vasodilatation in arteries of hypertensive animals [ 19 , 20 ]. THC itself (international non-proprietary name, dronabinol), its synthetic analog nabilone, and the mixture of THC and cannabidiol (nabiximols) are approved by the US Food and Drug Administration and other national or supranational drug agencies for some of the above indications ( Table 1 [ 21 ]).…”

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses

“…High affinity, high efficacy CB1R agonists that are relatively easy to synthesize have been obtained and used by humans outside of medical advice for recreational and medicinal purposes (Coronado-Álvarez et al, 2021). These synthetic cannabinoid agonists can have serious adverse effects and have been associated with a wide array of severe psychiatric, cardiovascular, and gastrointestinal consequences (Alipour, Patel, Shabbir, & Gabrielson, 2019; Courts, Maskill, Gray, & Glue, 2016) and lethality (Giorgetti, Busardò, Tittarelli, Auwärter, & Giorgetti, 2020).…”